ClinicalTrials.gg
CompletedNCT03417661Updated Jul 22, 2020

An Evaluation of the Efficacy of HEXI-PREP by Clinell Wipes

A Phase 3 interventional study of HEXI-PREP By Clinell Wipes and Chloraprep in Antimicrobial Effect, sponsored by Gama Healthcare Ltd.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-22.

Sponsored by Gama Healthcare Ltd. · Phase 3, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study evaluates the antimicrobial properties of HEXI-PREP by Clinell compared to both a negative and a positive control product.

Read the detailed description

HEXI-PREP by Clinell is a sterile single sachet wipe containing chlorhexidine gluconate and isopropyl alcohol. Both active ingredients are well-established ingredients commonly used for their disinfectant properties.

This trial is designed to assess the superiority of HEXI-PREP by Clinell Wipe against a negative control, and also to demonstrate the relative efficacy of HEXI-PREP by Clinell WIpe against a similar commercially available product.

02

Conditions studied

  • Antimicrobial Effect
03

In context

Lead sponsor

This is the only study on the registry with Gama Healthcare Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants 18 - 70 years, who have provided written to participate in the study
  • Test sites with a bacterial baseline count of ≥ 5.0 log10/cm2 at the inguinal (groin) test administration sites. ≥4.0 log10/cm2 at the abdominal test site and >3.0 log10/cm2 at the clavicular and/or median cubital regions at Day - 5 of screening
  • Participants, who in the opinion of the Investigator, are in suitable health for inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • Exposure of the test sites to strong detergents, solvents or other irritants during the 14- day pre-test conditioning period or during the test period.
  • Use of systemic or topical antibiotic medications, medications or any other product known to affect the normal microbial flora of the skin, up to 1 month prior to the screening period, during the 14-day pre-test conditioning period or during the test period.
  • Any known allergies to latex (rubber), alcohols, tape adhesives or to common antibacterial agents found in soaps, lotions or ointments, particularly chlorhexidine gluconate or chlorine.
  • Active skin rashes or breaks in the skin at the test site.
  • Active skin diseases or inflammatory skin conditions including contact dermatitis within 10cm of the test site.
  • Showering or bathing after the Day -5 baseline sampling and unwilling to refrain from showering or bathing whilst at Surrey CRC (Day 0 to Day 1).
  • Participation in another clinical trial within 90 days preceding randomisation.
  • Pregnant or breastfeeding women.
  • Any other medical condition, which in the opinion of the Investigator, should preclude participation.
  • Unwillingness to fulfil the performance requirements of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    HEXI-PREP By Clinell Wipes vs Placebo

    Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.

    Drug: HEXI-PREP By Clinell Wipes · Drug: Placebos

  • Experimental
    HEXI-PREP By Clinell Wipes vs Chloraprep

    Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.

    Drug: HEXI-PREP By Clinell Wipes · Drug: Chloraprep

  • Experimental
    Chloraprep vs Placebo

    Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.

    Drug: Chloraprep · Drug: Placebos

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction of bacterial load at each test site.

    Reduction in bacterial load of the test product in comparison to a negative control.

    Time frame: 1 and 10 minutes after application.

Secondary outcomes

  1. Persistence of reduction in bacterial load at each test site.

    Reduction in bacterial load of the test product in comparison to a negative control over a longer duration.

    Time frame: 30 minutes - 24 hours

  2. Relative efficacy compared to a positive control

    To assess the reduction in bacterial load after application when compared to a similar commercially available product.

    Time frame: 1-10 minutes, and 30 minutes - 24 hours

  3. Number of participants with treatment-related adverse events as assessed by a 5-point scale based on comment from the participant, and recorded assessments of erythema and oedema.

    Assessed by comments from the participant logged on a five-point scale, and recorded assessments of erythema and oedema by the investigator. Erythema and oedema are each assessed on a five-point scale of none to severe.

    Time frame: From application

07

Study locations

1 site
  • Surrey Clinical Research Centre
    Guildford, Surrey, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Jun 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 31, 2018
StartActual
Jun 29, 2018
Primary completionActual
Jun 6, 2019
CompletionActual
Sep 18, 2019
Last update
Jul 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03417661
Lead sponsor
Gama Healthcare Ltd.
Responsible party
Sponsor
First posted
Jan 31, 2018
Start date
Jun 29, 2018
Primary completion
Jun 6, 2019
Completion
Sep 18, 2019
Last update
Jul 22, 2020

Study contacts

Daryl Bendel
principal investigator · Medical Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chlorhexidine/Ethyl Alcohol Mouthwash

Start the discussion